Population-based monitoring of cancer patient survival in situations with imperfect completeness of cancer registration by Brenner, H & Hakulinen, T
Short Communication
Population-based monitoring of cancer patient survival in
situations with imperfect completeness of cancer registration
H Brenner*,1 and T Hakulinen
2
1Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Strasse 20, D-69115 Heidelberg, Germany;
2Finnish Cancer Registry,
Institute for Statistical and Epidemiological Cancer Research, Liisankatu 21 B, FIN-00170 Helsinki, Finland
Selective underascertainment of cases may bias estimates of cancer patient survival. We show that the magnitude of potential bias
strongly depends on the time periods affected by underascertainment and on the type of survival analysis (cohort analysis vs period
analysis). We outline strategies on how to minimise or overcome potential biases.
British Journal of Cancer (2005) 92, 576–579. doi:10.1038/sj.bjc.6602323 www.bjcancer.com
Published online 18 January 2005
& 2005 Cancer Research UK
Keywords: cancer registries; prognosis; statistical methods; survival analysis
                            
Population-based monitoring of cancer patient survival is an
important task of cancer registries (e.g. Berrino et al, 1995, 1999,
2003; Dickman et al, 1999; Talba ¨ck et al, 2003). As with other
cancer statistics, the validity of population-based cancer survival
estimates depends on the quality of the cancer registry data. Most
obviously, a minimum requirement is reliable follow-up of patients
with respect to vital status. The validity of survival estimates may
also depend on completeness of cancer registration (Monnet et al,
1998; Prior et al, 1998). In particular, selective underascertain-
ment of patients with a good prognosis may lead to under-
estimation of cancer patient survival, whereas an opposite effect
could result from selective underascertainment of patients with
poor prognosis. The aim of this paper is to assess the impact of
various patterns of incompleteness of cancer registration on
population-based estimates of cancer patient survival in a quanti-
tative manner.
MATERIAL AND METHODS
Database
Our analysis is based on data from the nationwide Finnish Cancer
Registry whose true completeness (in terms of ascertainment of
both incident cases and follow-up status) is known to be very close
to 100% (Teppo et al, 1994). We included patients, aged 15 years or
older, with a first diagnosis of one of the six most common forms
of cancer in Finland between 1990 and 1999.
Statistical analysis
The impact of underascertainment of incident cases was assessed
for 5-year relative survival rates (Ederer et al, 1961), which were
derived using Hakulinen’s (1982) method by two different
approaches illustrated in Figure 1. With the first approach, 5-year
survival rates were calculated for the cohort of patients diagnosed
in 1990–1994 and followed with respect to vital status until the
end of 1999 (solid frame). The second approach is the so-called
period analysis, which has first been proposed a few years ago to
provide more up-to-date estimates of cancer patient survival
(Brenner and Gefeller 1996, 1997). Here, 5-year relative survival
estimates for the 1995–1999 period are reported, which exclusively
reflect the survival experience of patients during those years
(dashed frame).
To assess the impact of incompleteness of registration either in
the earlier or in the more recent years of the database, we carried
out both a cohort analysis for the 1990–1994 cohort and a period
analysis for the 1995–1999 period, assuming underascertainment
of the following cases either in 1990–1994 or in 1995–1999 in
different scenarios: (a) all cases, (b) only cases dying within 5 years
following diagnosis and (c) only cases still alive 5 years following
diagnosis.
Expected survival estimates for 80, 90, or 95% completeness of
ascertainment of the specified patient groups were derived by
weighted survival analyses, where a weight of 0.8, 0.9, or 0.95,
respectively, was assigned to patients in these groups, and a weight
of 1 was assigned to all other patients using a recently described
SAS macro (Brenner et al, 2004a).
RESULTS
Table 1 shows the numbers of patients by cancer site included in
the analysis, as well as the estimates of 5-year relative survival
obtained by the cohort method and by the period method from the
full (presumably virtually complete) database. The most common
form of cancer in Finland in 1990–1999 was breast cancer,
followed by prostate cancer and lung cancer. Estimates of 5-year
relative survival obtained by cohort analysis ranged from 81.6%
for patients with breast cancer to 9.2% for patients with lung
cancer. Period estimates were somewhat higher, with differences
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cancer). These differences reflect improvements in survival in the
1990s.
Unselective underascertainment of cases diagnosed in 1990–
1994 would not affect cohort estimates of 5-year relative survival
for patients diagnosed in those years. The 1995–1999 period
estimates would be altered to some very minor extent (o0.3%
units in all scenarios) by giving less weight to patients diagnosed in
1990–1994 compared to those diagnosed in 1995–1999. To save
space, these results are not shown in a table.
As expected from theory, selective underascertainment of cases
diagnosed in 1990–1994, who died within 5 years, would lead to
overestimation of 5-year relative survival for the 1990–1994 cohort
(see Table 2). For the most extreme scenarios, with selective
underascertainment of 20% of these patients, 5-year relative
survival would be overestimated by between 2.0% units (lung
cancer) and 7.6% units (prostate cancer). The period estimates of
5-year relative survival for the 1995–1999 period would be much
less affected by selective underascertainment of dying patients
diagnosed in those earlier years.
By contrast, selective underascertainment of patients diagnosed
in 1990–1994, who were still alive 5 years after diagnosis, would
lead to underestimation of 5-year relative survival for the 1990–
1994 cohort. Again, the bias would be quite small for lung cancer
with its poor prognosis, and somewhat more pronounced for
cancers with intermediate or more favourable prognosis. The
period estimates of 5-year relative survival for the 1995–1999
period would again be much less affected by selective under-
ascertainment of surviving patients diagnosed in those earlier
years.
Obviously, underascertainment of cases diagnosed in 1995–
1999 would not affect the survival estimates for the 1990–1994
cohort at all. The period estimates would also remain essentially
unaffected if the underascertainment was unselective, that is, the
same for patients who died and who did not die in 1995–1999. The
period estimates for the 1995–1999 period could, however, be
biased to some extent by selective underascertainment of patients
diagnosed in that period (see Table 3). The potential bias would
again be smallest for lung cancer with its poor prognosis, and
somewhat more pronounced for cancers with intermediate or
more favourable prognosis.
DISCUSSION
Both cohort analysis and the more recently introduced period
analysis are now well-established prototypes of population-based
monitoring of cancer patient survival. Cohort analysis provides
Table 1 Numbers and 5-year relative survival of patients diagnosed with
common forms of cancer above 14 years of age in Finland in 1990–1999
5-year relative survival (%)
Site n
a
1990–1994
cohort
1995–1999
period
Difference
(% units)
Stomach 9262 25.9 28.8 +2.9
Colon 11487 53.3 57.8 +4.5
Rectum 7715 50.9 54.9 +4.0
Lung 20201 9.2 9.5 +0.3
Breast 29859 81.6 83.2 +1.6
Prostate 22491 66.5 73.9 +7.4
aTotal number of patients in 1990–1999.
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Figure 1 Database for calculating 5-year survival by the cohort method
(solid frame) and the period method (dashed frame). The numbers within
the cells indicate the years since diagnosis.
Table 2 Estimates of 5-year relative survival (%) for the 1990–1994 cohort and for the 1995–1999 period expected with various patterns and various
levels of selective underascertainment of cases diagnosed in 1990–1994
1990–1994 cohort 1995–1999 period
Selective underascertainment of
Case ascertainment Case ascertainment
Site 80% 90% 95% 100% 80% 90% 95% 100%
cases dying within 5 years Stomach 30.7 28.1 27.0 25.9 30.6 29.7 29.2 28.8
Colon 59.9 56.4 54.8 53.3 60.3 59.0 58.4 57.8
Rectum 57.5 54.0 52.4 50.9 57.6 56.2 55.6 54.9
Lung 11.2 10.1 9.6 9.2 10.5 10.0 9.7 9.5
Breast 85.8 83.7 82.6 81.6 85.2 84.2 83.7 83.2
Prostate 74.1 70.1 68.3 66.5 77.7 75.8 74.9 73.9
cases still alive after 5 years Stomach 21.8 23.9 24.9 25.9 27.0 27.9 28.4 28.8
Colon 46.9 50.2 51.8 53.3 55.2 56.6 57.2 57.8
Rectum 44.6 47.9 49.4 50.9 51.9 53.5 54.2 54.9
Lung 7.5 8.3 8.8 9.2 8.6 9.1 9.3 9.5
Breast 77.0 79.5 80.6 81.6 81.0 82.2 82.7 83.2
Prostate 59.0 63.0 64.8 66.5 70.2 72.2 73.1 73.9
Population-based monitoring of cancer patient survival
H Brenner and T Hakulinen
577
British Journal of Cancer (2005) 92(3), 576–579 & 2005 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
ysurvival information on real cohorts of patients diagnosed within
certain calendar years. Period analysis provides more up-to-date
survival estimates, but these estimates pertain to patients
diagnosed in a wider range of years of diagnosis and can less
readily be linked to the patterns of early diagnosis and medical
care during a defined time span (Brenner et al, 2004b). Hence, the
choice between both methods would typically depend on the
primary goal of the analysis.
This paper illustrates in a quantitative manner that the
completeness of cancer registry data during various years may
be an additional criterion for the choice of either method. For
example, during the build-up phase of a new cancer registry, when
completeness tends to increase over time, one might prefer
calculation of period estimates over calculation of cohort estimates
as the former may be less prone to bias by selective under-
registration during the early years of registration. On the other
hand, period estimates may be more prone to bias than cohort
estimates if the completeness of the most recent available data is
questionable due to delayed recording of some proportion of cases.
In practice, however, the latter concern is typically relevant for a
maximum of one or two of the most recent years for which data
would be available, and one might still use a period analysis after
excluding those years, either entirely or partly by means of a
‘hybrid’ type of analysis (Brenner and Rachet, 2004c). As period
analysis has been shown to advance detection of trends in 5-, 10-,
15-, and 20-year survival rates by almost 5, 10, 15, and 20 years,
respectively (Brenner and Hakulinen, 2002a), the slight loss of up-
to-dateness that would follow from such a decision would still be
almost negligible compared to the gain in up-to-dateness by the
use of period analysis rather than cohort analysis. Furthermore,
the magnitude of potential bias would have to be weighed against
the often more substantial underestimation of current survival by
cohort estimates (Brenner and Hakulinen 2002a,b; Brenner et al,
2002c; Talba ¨ck et al, 2004).
Which, if any, of the potential sources of bias may be relevant in
a given study strongly depends on the specific circumstances
under which a cancer registry is operating. Therefore, when
choosing an analytic strategy, the specific circumstances of
registration of the registries involved should be taken into account
along with other aspects, such as up-to-dateness of cancer survival
data.
When looking at our data, the following limitations should be
considered. Results were presented for 5-year relative survival
rates only, as these are the survival rates most commonly reported
by population-based cancer registries. We also carried out
analogous analyses for 5-year absolute survival rates. However,
patterns were generally very similar, and they were therefore not
shown separately to save space. Finally, we focused on very
specific, relatively extreme patterns of entirely selective under-
ascertainment of cases to illustrate the general principles. In
practice, the impact of underascertainment of patients with
relatively poor prognosis and of patients with relatively good
prognosis would usually partly (and sometimes fully) cancel out,
leading to smaller biases than those shown in our analysis.
Despite these limitations, our analysis illustrates the
potential impact of incompleteness of cancer registration on
various types of population-based monitoring of survival. The
identified patterns could be valuable for decisions regarding
the best analytic strategy in specific situations. The analyses
also underline once more the crucial requirement of high levels
of completeness for the use of population-based cancer regis-
tration.
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